Kajian klinikal Depresi di Connecticut
15 kajian untuk Depresi sedang mencari peserta di lokasi di Connecticut.
Bandar di Connecticut
Teks kajian rasmi (Bahasa Inggeris)
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
- Yale University, New Haven
Mengambil pesertaFasa 2
Umur 40 hingga 80 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07610369A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Yale School of Medicine - Yale Program for Psychedelic Science, New Haven
Mengambil pesertaFasa 3
Umur 18 hingga 85 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06793397A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Cromwell
Mengambil pesertaFasa 2
Umur 18 hingga 65 · Semua jantina · Dikemas kini 14 Sep 2026 · NCT07065240A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Institute of Living, Hartford
Mengambil pesertaFasa 3
Umur 18 hingga 74 · Semua jantina · Dikemas kini 8 Sep 2026 · NCT07076407PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
- Mood Institute, Milford
- Yale School of Medicine, New Haven
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06713616A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Yale University School of Medicine, New Haven
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT07412756E-Mindfulness Approaches for Living After Breast Cancer
- Stamford Hospital/Bennett Cancer Center, Stamford
Mengambil pesertaFasa 3
Umur 18 hingga 50 · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT06748222A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- Ct Clinical Research Associates, Cromwell
Mengambil pesertaFasa 3
Umur 18 hingga 74 · Semua jantina · Dikemas kini 3 Ogo 2026 · NCT06775379Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Cromwell
- Neurocrine Clinical Site, Farmington
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Jul 2026 · NCT06966401Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
- Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,, West Haven
Mengambil pesertaFasa 1Sukarelawan sihat dialu-alukan
Umur 21 hingga 65 · Semua jantina · Dikemas kini 16 Jun 2026 · NCT06671977Assessing the Effectiveness of Digital Wellness Modules on Perceived Quality of Life
- Yale University, New Haven
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 18 hingga 65 · Semua jantina · Dikemas kini 29 Mei 2026 · NCT05810259The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
- VA Connecticut Healthcare System, West Haven
Mengambil pesertaFasa 2
Umur 21 hingga 65 · Semua jantina · Dikemas kini 6 Mei 2026 · NCT05786066Stress and Pain in People Living With HIV
- The Yale Stress Center, New Haven
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 18 hingga 68 · Semua jantina · Dikemas kini 27 Apr 2026 · NCT06784908External Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy
- https://public.smart-trial.co/#/public/649d77f0e8f8d0fb993d0c61/6626f6a04f0a3c7dd0860e14/662726d84f0a3c7dd08aeaa0/signup?lang=en-us&enforceL, Darien
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 44 · Wanita · Dikemas kini 15 Apr 2026 · NCT06788977Open-Label Psilocybin Study in Transdiagnostic Population
- Connecticut Mental Health Center - Yale School of Medicine, New Haven
Mengambil pesertaFasa 1Sukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Mac 2026 · NCT06442423Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.